Department of Psychiatry, University Hospital Marqués de Valdecilla, School of Medicine, University of Cantabria, Santander, Spain.
Psychiatry Res. 2010 Feb 28;175(3):189-94. doi: 10.1016/j.psychres.2008.12.011.
There is substantial evidence suggesting that individual variability in antipsychotic treatment response could be genetically determined. Variations in several serotonin transporter (5-HTT) gene polymorphisms have been associated with antipsychotic response among chronic patients with schizophrenia, although their implication in early response among first-episode patients remains unclear. Two polymorphisms in the 5-HTT gene (a 44 bp insertion/deletion in the promoter region and the functional polymorphism rs25531) were genotyped in a sample of 147 drug-naïve patients experiencing a first episode of a non-affective psychosis. Early (6 weeks) response to antipsychotic treatment with haloperidol, olanzapine or risperidone was assessed with the Brief Psychiatric Rating Scale, the Scale for the Assessment of Positive Symptoms, and the Scale for the Assessment of Negative Symptoms. No clear association was found between the rs25531 variant and treatment response. However, significant associations were observed between 5-HTT-LPR variants and early negative symptom response among first-episode patients with psychosis. Our results suggest a minor contribution to antipsychotic drug response of genetic alterations in the 5-HTT gene.
有大量证据表明，抗精神病药物治疗反应的个体差异可能是由遗传决定的。几种 5-羟色胺转运体（5-HTT）基因多态性与慢性精神分裂症患者的抗精神病反应有关，尽管它们在首发患者的早期反应中的意义尚不清楚。在一个 147 名未经药物治疗的首发非情感性精神病患者的样本中，对 5-HTT 基因中的两个多态性（启动子区域的 44 个碱基对插入/缺失和功能性多态性 rs25531）进行了基因分型。使用简明精神病评定量表、阳性症状评定量表和阴性症状评定量表评估抗精神病药物（氟哌啶醇、奥氮平或利培酮）治疗 6 周的早期反应。rs25531 变体与治疗反应之间没有明显的关联。然而，在首发精神病患者中，5-HTT-LPR 变体与早期阴性症状反应之间存在显著关联。我们的结果表明，5-HTT 基因的遗传改变对抗精神病药物反应的贡献较小。
